Professor Ian Frazer AC is Chief Executive Officer (CEO) and Director of Research of Translational Research Institute (TRI) Pty Ltd in Brisbane, Australia. In this role, Professor Frazer heads an expert cohort of over 650 researchers from four leading medical research institutes.
TRI combines the collective intellect from The University of Queensland Diamantina Institute (UQDI), Queensland University of Technology Institute for Biomedical and Health Innovation (IHBI), Mater Research and Princess Alexandra Hospital Centres for Health Research, along with biopharmaceutical manufacturer, DSM Biologics.
An Australian-first, the Institute represents the future of biomedical research. Quite simply, TRI’s ‘bench to bedside’ capability means research, clinical trial and manufacture of breakthrough treatment and therapies for common and chronic illness and disease occurs in a single location.
Internationally renowned for the co-creation of the technology for the cervical cancer vaccines, Professor Frazer began his career as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, Professor Frazer accepted a teaching post with The University of Queensland and was appointed Director of The University of Queensland Diamantina Institute in 1991. In early 2011, Professor Frazer relinquished directorship of the Institute to commence in-post as CEO of the TRI. He retains an active research program at the Institute in immune responses to cancer and cancer immunotherapy.
Professor Frazer was awarded the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister's Prize for Science, the 2008 Balzan Prize for Preventive Medicine, the 2009 Honda Prize and in 2011, was elected as a Fellow of the esteemed Royal Society of London. In 2012, Professor Frazer was appointed a Companion of the Order of Australia (AC) in the Queen’s Birthday Honours.
Papillomaviruses come in many types, some of which cause hand or genital warts. Prof Harald Zur Hausen postulated in the early 1980s that at least one type of papillomavirus might cause cervical cancer, and we now recognize that all cervical cancer is caused by persisting infection with one of ~10 types of papillomavirus. Developing a vaccine was hindered by inability to grow papillomavirus in the laboratory, and facilitated by development of recombinant DNA technology which enabled production of papillomavirus virus like particles. These non-infectious particles mimic the virus and induce a protective immune response against papillomavirus infection when delivered as a vaccine. Introduction of immunisation programs using papillomavirus virus like particles have already nearly eliminated genital warts in Australia, and have sharply reduced the number of infections with the papillomavirus types responsible for cervical cancer. The major challenge is to ensure vaccination in the developing world where up to 250,000 women each year die of cervical cancer.
Event Manager: Mitchell Piercey
Phone: (02) 6201 9462
Professor Ian Frazer AC is Chief Executive Officer (CEO) and Director of Research of Translational Research Institute (TRI) Pty Ltd in Brisbane, Australia. In this role, Professor Frazer heads an expert cohort of over 650 researchers from four leading medical research institutes.
TRI combines the collective intellect from The University of Queensland Diamantina Institute (UQDI), Queensland University of Technology Institute for Biomedical and Health Innovation (IHBI), Mater Research and Princess Alexandra Hospital Centres for Health Research, along with biopharmaceutical manufacturer, DSM Biologics.
An Australian-first, the Institute represents the future of biomedical research. Quite simply, TRI’s ‘bench to bedside’ capability means research, clinical trial and manufacture of breakthrough treatment and therapies for common and chronic illness and disease occurs in a single location.
Internationally renowned for the co-creation of the technology for the cervical cancer vaccines, Professor Frazer began his career as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, Professor Frazer accepted a teaching post with The University of Queensland and was appointed Director of The University of Queensland Diamantina Institute in 1991. In early 2011, Professor Frazer relinquished directorship of the Institute to commence in-post as CEO of the TRI. He retains an active research program at the Institute in immune responses to cancer and cancer immunotherapy.
Professor Frazer was awarded the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister's Prize for Science, the 2008 Balzan Prize for Preventive Medicine, the 2009 Honda Prize and in 2011, was elected as a Fellow of the esteemed Royal Society of London. In 2012, Professor Frazer was appointed a Companion of the Order of Australia (AC) in the Queen’s Birthday Honours.
Papillomaviruses come in many types, some of which cause hand or genital warts. Prof Harald Zur Hausen postulated in the early 1980s that at least one type of papillomavirus might cause cervical cancer, and we now recognize that all cervical cancer is caused by persisting infection with one of ~10 types of papillomavirus. Developing a vaccine was hindered by inability to grow papillomavirus in the laboratory, and facilitated by development of recombinant DNA technology which enabled production of papillomavirus virus like particles. These non-infectious particles mimic the virus and induce a protective immune response against papillomavirus infection when delivered as a vaccine. Introduction of immunisation programs using papillomavirus virus like particles have already nearly eliminated genital warts in Australia, and have sharply reduced the number of infections with the papillomavirus types responsible for cervical cancer. The major challenge is to ensure vaccination in the developing world where up to 250,000 women each year die of cervical cancer.
Shine Dome,9 Gordon Street Australian Capital Territory false DD/MM/YYYYEvent Manager: Mitchell Piercey
Phone: (02) 6201 9462
© 2024 Australian Academy of Science
